ERAMET Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
- Coordinator
- Universite De Namur, Belgium
- Runs
- 1 January 2024 to 31 December 2027
- Status
- Running
- EU funding
- €3.9m
- Total cost
- €3.9m
- Partners
- 19 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101137141
What the project is doing
In the project's own words, from its summary on CORDIS.
ERAMET will provide an integrated approach for developers and regulators’ decision-making for paediatric and orphan drugs, centred on the drug development questions. This will constitute a transparent ecosystem for drug development and assessment, that will facilitate the adoption of modelling and simulation (M&S) methods and related data types (including real word data such as registries and electronic healthcare data).
The overall objective of ERAMET is to provide and implement a framework for establishing the credibility of M&S methods and related results as sources of evidence within regulatory procedures. The ecosystem proposed by ERAMET will be based on three pillars: (1) A repository connecting questions, data and methods.(2) The development and validation of high-quality standards for data and analytical methods (including M&S and hybrid approaches).
These will cover computational M&S, digital twins, AI, hybrid approaches, standard statistics and pharmacometrics, as analytical methods and alternative data types and sources such as RWD, eHealth data, registries, historical regulatory submissions, scientific and (non)clinical trials). (3) An AI-based platform that will automate and optimise the data collection, formatting and modelling and simulation analysis and implement the credibility assessment.
As part of ERAMET, the ecosystem will be applied to five use-cases including paediatric extrapolation and characterisation of drug benefit/risk in 4 groups of rare diseases, namely ataxia, transfusion dependent haemoglobinopathies, bronchopulmonary dysplasia, and paediatric tuberculosis. Each of the use-case is planned to lead to submission and regulatory approval of at least one validated M&S tool via the EMA qualification procedure.
Training will be proposed to familiarise regulatory assessors, drug developers and clinical researchers with this new approach.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universite De Namur | Namur | Belgium | Coordinator |
| European Business Summit Network | Elsene | Belgium | Participant |
| Federal Agency for Medicines and Health Products | Sint-Joost-Ten-Node | Belgium | Participant |
| Athina-Erevnitiko Kentro Kainotomias Stis Technologies Tis Pliroforias, Ton Epikoinonion Kai Tis Gnosis | Maroussi | Greece | Participant |
| Agencia Espanola De Medicamentos Y Productos Sanitarios | Madrid | Spain | Associatedpartner |
| Universitat De Valencia | Valencia | Spain | Participant |
| Agence Nationale De Securite Du Medicament Et Des Produits De Sante | Saint Denis Cedex | France | Participant |
| Consorzio per Valutazioni Biologiche E Farmacologiche | Bari | Italy | Participant |
| Fondazione per La Ricerca Farmacologica Gianni Benzi Ets | Valenzano | Italy | Third party |
| Universita Degli Studi Di Catania | Catania | Italy | Participant |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Participant |
| Agentschap College Ter Beoordeling Van Geneesmiddelen | Utrecht | Netherlands | Participant |
| Aparito Netherlands BV | Leiden | Netherlands | Participant |
| Ine Blankenberg Skottheim Rusten | Kragero | Norway | Participant |
| Systems Resource Lab AS | Kragero | Norway | Participant |
| Aridhia Informatics Limited | Glasgow | United Kingdom | Associatedpartner |
| Certara UK Limited | London | United Kingdom | Associatedpartner |
| University College London | London | United Kingdom | Associatedpartner |
| University of Warwick | Coventry | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI